Borderline personality disorder: Current drug treatments and future prospects

Therapeutic Advances in Chronic Disease

Volumn 1, Issue 2, 2010, Pages 59-66

  Olabi, Bayanne ^a   Hall, Jeremy ^a  

^a ROYAL EDINBURGH HOSPITAL   (United Kingdom)

Author keywords

antidepressants; antipsychotic medications; borderline personality disorder; epigenetics; mood stabilizers

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROPEPTIDE; OLANZAPINE; OPIATE ANTAGONIST; OPIATE PEPTIDE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VASOPRESSIN;

ARTICLE; AUTOMUTILATION; BORDERLINE STATE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; IMPULSIVENESS; LIFE STRESS; MENTAL HEALTH SERVICE; META ANALYSIS (TOPIC); MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF CONCEPT; SUICIDE;

EID: 79952924309     PISSN: 20406223     EISSN: None     Source Type: Journal    
DOI: 10.1177/2040622310368455     Document Type: Review

References (108)

1. Abraham, P.F. and Calabrese, J.R. ( 2008) Evidence-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics ? J Affect Disord 111: 21-30.
2. American Psychiatric Association (2001) Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 158: 1-52.
3. Ball, J.S. and Links, P.S. (2009) Borderline personality disorder and childhood trauma: Evidence for a causal relationship. Curr Psychiatry Rep 11: 63-68.
4. Bellino, S., Paradiso, E. and Bogetto, F. ( 2008) Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs 22: 671-692.
5. Benedetti, F., Sforzini, L. and Colombo, C. ( 1998) Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 59: 103-107.
6. Bielsky, I.F., Hu, S.B., Szegda, K.L., Westphal, H. and Young, L.J. ( 2004) Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 29: 483-493.
7. Binks, C.A., Fenton, M., McCarthy, L., Lee, T., Adams, C.E. and Duggan, C. ( 2006) Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 25: CD005653.
8. Bodnar, R.J. ( 2009) Endogenous opiates and behavior: 2008. Peptides 30: 2432-2479.
9. Bogenschutz, M.P. and Nurnberg, G.H. ( 2004) Olanzapine versus placebo in the treatment of BPD. J Clin Psychiatry 65: 104-109.
10. Bowden, C.L. ( 2007) Spectrum of effectiveness of valproate in neuropsychiatry. Expert Rev Neurother 7: 9-16.
11. Caldwell, H.K., Lee, H.J., Macbeth, A.H. and Young III, W.S. ( 2008) Vasopressin: Behavioral roles of an ‘original’ neuropeptide. Prog Neurobiol 84: 1-24.
12. Carrasco, J.L., Dıaz-Marsa, M., Pastrana, J.I., Molina, R., Brotons, L., Lopez-Ibor, M.I. et al. (2007) Hypothalamic-pituitary-adrenal axis response in borderline personality disorder without post-traumatic features. Br J Psychiatry 190: 357-358.
13. Casner, J.A., Weinheimer, B. and Gualtieri, C.T. ( 1996) Naltrexone and self-injurious behavior: A retrospective population study. J Clin Psychopharmacol 16: 389-394.
14. Clarkin, J.F., Widiger, T.A., Frances, A., Hurt, S.W. and Gilmore, M. ( 1983) Prototypic typology and the borderline personality disorder. J Abnorm Psychol 92: 263-275.
15. Coccaro, E.F. ( 1998) Clinical outcome of psycho-pharmacologic treatment of borderline and schizotypal personality disordered subjects. J Clin Psychiatry 59(Suppl 1): 30-35.
16. Coccaro, E.F. and Kavoussi, R.J. ( 1997) Fluoxetine and impulsive aggressive behavior in personality disordered subjects. Arch Gen Psychiatry 54: 1081-1088.
17. Coccaro, E.F., Kavoussi, R.J., Hauger, R.L., Cooper, T.B. and Ferris, C.F. ( 1998) Cerebrospinal fluid vasopressin levels: Correlates with aggression and serotonin function in personality-disordered subjects. Arch Gen Psychiatry 55: 708-714.
18. Coid, J.W. ( 1993) An affective syndrome in psychopaths with borderline personality disorder? Br J Psychiatry 162: 641-650.
19. Coid, J., Allolio, B. and Rees, L.H. ( 1983) Raised plasma metenkephalin in patients who habitually mutilate themselves. Lancet 2: 545-546.
20. Comtois, K.A., Cowley, D.S., Dunner, D.L. and Roy-Byrne, P.P. ( 1999) Relationship between borderline personality disorder and Axis I diagnosis in severity of depression and anxiety. Am J Psychol 146: 490-495.
21. Cowdry, R.W. and Gardner, D.L. ( 1988) Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 45: 111-119.
22. Crowell, S.E., Beauchaine, T.P. and Linehan, M.M. (2009) A biosocial developmental model of borderline personality: Elaborating and extending Linehan's theory. Psychol Bull 135: 495-510.
23. Cushing, B.S. and Kramer, K.M. ( 2005) Mechanisms underlying epigenetic effects of early social experience: The role of neuropeptides and steroids. Neurosci Biobehav Rev 29: 1089-1105.
24. Davidson, K., Norrie, J., Tyrer, P., Gumley, A., Tata, P., Murray, H. et al. (2006) The effectiveness of cognitive behavior therapy for borderline personality disorder: Results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. J Pers Disord 20: 450-465.
25. de la Fuente, J. and Lotstra, F. ( 1994) A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 4: 479-486.
26. Dıaz-Marsa, M., Gonzalez Bardanca, S., Tarima, K., Garcıa-Albea, J., Navas, M. and Carrasco, J.L. ( 2008) Psychopharmacological treatment in borderline personality disorder. Actas Esp Psiquiatr 36: 39-49.
27. Dimeff, L.A., McDavid, J. and Linehan, M.M. ( 1999) Pharmacotherapy for borderline personality disorder: A review of the literature and recommendations for treatment. J Clin Psychol Med Settings 6: 113-138.
28. Frankenburg, F.R. and Zanarini, M.C. ( 2002) Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. J Clin Psychiatry 63: 442-446.
29. Göttlicher, M. ( 2004) Valproic acid: An old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83(Suppl 1): S91-S92.
30. Göttlicher, M., Minucci, S., Zhu, P., Krämer, O.H., Schimpf, A., Giavara, S. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
31. Grootens, K.P. and Verkes, R.J. ( 2005) Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry 38: 20-23.
32. Haddad, P.M., Das, A., Ashfaq, M. and Wieck, A. (2009) A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 5: 539-551.
33. Hall, J., Olabi, B., Lawrie, S.M. and McIntosh, A.M. ( 2010) Hippocampal and amygdala volumes in borderline personality disorder: a meta-analysis of magnetic resonance imaging studies. Pers Mental Heal (In press).
34. Hallmayer, J.F. ( 2003) Olanzapine and women with borderline personality disorder. Curr Psychiatry Rep 5: 175.
35. Handel, A.E., Ebers, G.C. and Ramagopalan, S.V. (2010) Epigenetics: Molecular mechanisms and implications for disease. Trends Mol Med 16: 7-16.
36. Herpertz, S.C., Zanarini, M., Schulz, C.S., Siever, L., Lieb, K. and Möller, H.J. WFSBP Task Force on Personality Disorders. ( 2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 8: 212-244.
37. Hollander, E., Allen, A., Lopez, R.P., Bienstock, C.A., Grossman, R., Siever, L.J. et al. (2001) A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 62: 199-203.
38. Kantrowitz, J.T. and Citrome, L. ( 2008) Olanzapine: Review of safety 2008. Expert Opin Drug Saf 7: 761-769.
39. Kars, H., Broekema, W., Glaudemans-van Gelderen, I., Verhoeven, W.M. and van Ree, J.M. ( 1990) Naltrexone attenuates self-injurious behavior in mentally retarded subjects. Biol Psychiatry 27: 741-746.
40. Kazantsev, A.G. and Thompson, L.M. ( 2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7: 854-868.
41. Kendall, T., Pilling, S., Tyrer, P., Duggan, C., Burbeck, R., Meader, N. et al. Guideline Development Groups. ( 2009) Borderline and antisocial personality disorders: Summary of NICE guidance. BMJ 338: b93.
42. Kroll, J. and Ogata, S. ( 1987) The relationship of borderline personality disorder to the affective disorders. Psychiatr Dev 5: 105-128.
43. Leyton, M., Okazawa, H., Diksic, M., Paris, J., Rosa, P., Mzengeza, S. et al. (2001) Brain regional alpha[11C]methyl-L-tryptophan trapping in impulsive subjects with borderline personality disorder. Am J Psychiatry 158: 775-782.
44. Lieb, K., Völlm, B., Rücker, G., Timmer, A. and Stoffers, J.M. (2010) Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 196: 4-12.
45. Lieb, K., Zanarini, M.C., Schmahl, C., Linehan, M.M. and Bohus, M. ( 2004) Borderline personality disorder. Lancet 364: 453-461.
46. Links, P.S., Boggild, A. and Sarin, N. ( 2001) Psychopharmacology of personality disorders: Review and emerging issues. Curr Psychiatry Rep 3: 70-76.
47. Links, P.S., Heslegrave, R. and van Reekum, R. ( 1999) Impulsivity: Core aspect of borderline personality disorder. J Pers Disord 13: 1-9.
48. Links, P., Steiner, M., Boiago, I. and Irwin, D. ( 1990) Lithium therapy for borderline patients: Preliminary findings. J Pers Disord 4: 173-181.
49. Loew, T.H., Nickel, M.K., Muehlbacher, M., Kaplan, P., Nickel, C., Kettler, C. et al. (2006) Topiramate treatment for women with borderline personality disorder: A double-blind, placebo-controlled study. J Clin Psychopharmacol 26: 61-66.
50. McGowan, P.O. and Szyf, M. ( 2010) The epigenetics of social adversity in early life: Implications for mental health outcomes. Neurobiol Dis [Epub ahead of print, 4 January].
51. Markovitz, P.J. ( 2004) Recent trends in the pharmacotherapy of personality disorders. J Pers Disord 18: 90-101.
52. Mercer, D., Douglass, A.B. and Links, P.S. (2009) Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. J Pers Disord 23: 156-174.
53. Nalivaeva, N.N., Belyaev, N.D. and Turner, A.J. (2009) Sodium valproate: An old drug with new roles. Trends Pharmacol Sci 30: 509-514.
54. Newton-Howes, G. and Tyrer, P. ( 2003) Pharmacotherapy for personality disorders. Expert Opin Pharmacother 4: 1643-1649.
55. Nickel, M.K., Nickel, C., Kaplan, P., Lahmann, C., Muhlbacher, M., Tritt, K. et al. (2005) Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biol Psychiatry 57: 495-499.
56. Nickel, M.K., Nickel, C., Mitterlehner, F.O., Tritt, K., Lahmann, C., Leiberich, P.K. et al. (2004) Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. J Clin Psychiatry 65: 1515-1519.
57. Nose, M., Cipriani, A., Biancosino, B., Grassi, L. and Barbui, C. ( 2006) Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 21: 345-353.
58. Nunes, P.M., Wenzel, A., Borges, K.T., Porto, C.R., Caminha, R.M. and de Oliveira, I.R. (2009) Volumes of the hippocampus and amygdala in patients with borderline personality disorder: A meta-analysis. J Pers Disord 23: 333-345.
59. Oldham, J.M., Bender, D.S., Skodol, A.E., Dyck, I.R., Sanislow, C.A., Yen, S. et al. (2004) Testing an APA practice guideline: Symptom-targeted medication utilization for patients with BPD. J Psychiatr Pract 10: 156-161.
60. Panksepp, J., Herman, B., Conner, R., Bishop, P. and Scott, J.P. ( 1978) The biology of social attachments: Opiates alleviate separation distress. Biol Psychiatry 13: 607-618.
61. Parsons, B., Quitkin, F.M., McGrath, P.J., Stewart, J.W., Tricamo, E., Ocepek-Welikson, K. et al. (1989) Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 25: 524-534.
62. Pinto, O.C. and Akiskal, H.S. ( 1998) Lamotrigine as a promising approach to borderline personality: An open case series without concurrent DSM-IV major mood disorder. J Affect Disord 51: 333-343.
63. Putnam, K.M. and Silk, K.R. ( 2005) Emotion dysregulation and the development of borderline personality disorder. Dev Psychopathol 17: 899-925.
64. Raj, Y.P. ( 2004) Psychopharmacology of borderline personality disorder. Curr Psychiatry Rep 6: 225-231.
65. Reynolds, G.P. and Kirk, S.L. (2010) Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther 125: 169-179.
66. Rifkin, A., Levitan, S.J., Galewski, J. and Klein, D.F. ( 1972) Emotionally unstable character disorder - a follow-up study, I: Description of patients and outcome. Biol Psychiatry 4: 65-79.
67. Rinne, T., van den Brink, W., Wouter, L. and van Dyck, R. ( 2002) SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 159: 2048-2054.
68. Rutten, B.P. and Mill, J. (2009) Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull 35: 1045-1056.
69. Salzman, C., Wolfson, A.N., Schatzberg, A., Looper, J., Henke, R., Albanese, M. et al. (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15: 23-29.
70. Sandman, C.A., Hetrick, W., Taylor, D.V. and ChiczDe Met, A. ( 1997) Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers. Am J Ment Retard 102: 182-199.
71. Santini, V., Gozzini, A. and Ferrari, G. ( 2007) Histone deacetylase inhibitors: Molecular and biological activity as a premise to clinical application. Curr Drug Metab 8: 383-393.
72. Saunders, K.E. and Hawton, K. (2009) The role of psychopharmacology in suicide prevention. Epidemiol Psichiatr Soc 18: 172-178.
73. Saunders, E.F. and Silk, K.R. (2009) Personality trait dimensions and the pharmacological treatment of borderline personality disorder. J Clin Psychopharmacol 29: 461-467.
74. Schmahl, C.G., McGlashan, T.H. and Bremner, J.D. ( 2002) Neurobiological correlates of borderline personality disorder. Psychopharmacol Bull 36: 69-87.
75. Schüle, C., Baghai, T.C., Eser, D. and Rupprecht, R. (2009) Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression. Expert Rev Neurother 9: 1005-1019.
76. Siever, L.J. ( 2008) Neurobiology of aggression and violence. Am J Psychiatry 165: 429-442.
77. Siever, L.J. and Davis, K.L. ( 1991) A psychobiological perspective on the personality disorders. Am J Psychiatry 148: 1647-1658.
78. Simpson, E.B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J. et al. (2004) Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 65: 379-385.
79. Skodol, A.E., Gunderson, J.G., Pfohl, B., Widiger, T.A., Livesley, W.J. and Siever, L.J. ( 2002) The borderline diagnosis: I. Psychopathology, comorbidity, and personality structure. Biol Psychiatry 51: 936-950.
80. Soler, J., Pascual, J.C. and Campins, J. ( 2005) Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for BPD. Am J Psychiatry 162: 1221-1224.
81. Soloff, P.H. ( 2000) Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 23: 169-192, ix.
82. Soloff, P.H., Cornelius, J., George, A., Nathan, S., Perel, J.M. and Ulrich, R.F. ( 1993) Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 50: 377-385.
83. Soloff, P.H., Meltzer, C.C., Greer, P.J., Constantine, D. and Kelly, T.M. ( 2000) A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry 47: 540-547.
84. Stanley, B., Sher, L., Wilson, S., Ekman, R., Huang, Y.Y. and Mann, J.J. ( 2009) Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters. J Affect Disord [Epub ahead of print, 24 November].
85. Stanley, B. and Siever, L.J. (2010) The interpersonal dimension of borderline personality disorder: Toward a neuropeptide model. Am J Psychiatry 167: 24-39.
86. Szyf, M., McGowan, P. and Meaney, M.J. ( 2008) The social environment and the epigenome. Environ Mol Mutagen 49: 46-60.
87. Szyf, M., Weaver, I. and Meaney, M. ( 2007) Maternal care, the epigenome and phenotypic differences in behavior. Reprod Toxicol 24: 9-19.
88. Teicher, M., Glod, C. and Aaronson, S. ( 1989) Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 25: 535-549.
89. Thompson, R., Gupta, S., Miller, K., Mills, S. and Orr, S. ( 2004) The effects of vasopressin on human facial responses related to social communication. Psychoneuroendocrinology 29: 35-48.
90. Tiefenbacher, S., Novak, M.A., Lutz, C.K. and Meyer, J.S. ( 2005) The physiology and neurochemistry of self-injurious behavior: A nonhuman primate model. Front Biosci 10: 1-11.
91. Torgersen, S., Kringlen, E. and Cramer, V. ( 2001) The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 58: 590-596.
92. Tritt, K., Nickel, C., Lahmann, C., Leiberich, P.K., Rother, W.K., Loew, T.H. et al. (2005) Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. J Psychopharmacol 19: 287-291.
93. Veenema, A.H., Blume, A., Niederle, D., Buwalda, B. and Neumann, I.D. ( 2006) Effects of early life stress on adult male aggression and hypothalamic vasopressin and serotonin. Eur J Neurosci 24: 1711-1720.
94. Weaver, I.C. ( 2007) Epigenetic programming by maternal behavior and pharmacological intervention. Nature versus nurture: Let's call the whole thing off. Epigenetics 2: 22-28.
95. Weaver, I.C., Champagne, F.A., Brown, S.E., Dymov, S., Sharma, S., Meaney, M.J. et al. (2005) Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: Altering epigenetic marking later in life. J Neurosci 25: 11045-11054.
96. Weaver, I.C.G., Cervoni, N., Champagne, F.A., D'Alessio, A.C., Sharma, S., Seckl, J.R. et al. (2004) Epigenetic programming by maternal behavior. Nat Neurosci 7: 847-854.
97. Widiger, T.A. and Weissman, M.M. ( 1991) Epidemiology in borderline personality disorder. Hosp Community Psychiatry 42: 1015-1021.
98. Yamamoto, Y., Cushing, B.S., Kramer, K.M., Epperson, P.D., Hoffman, G.E. and Carter, C.S. ( 2004) Neonatal manipulations of oxytocin alter expression of oxytocin and vasopressin immunoreactive cells in the paraventricular nucleus of the hypothalamus in a gender-specific manner. Neuroscience 125: 947-955.
99. Zanarini, M.C. ( 2004) Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep 6: 55-70.
100. Zanarini, M.C. ( 2009) Psychotherapy of borderline personality disorder. Acta Psychiatr Scand 120: 373-377.
101. Zanarini, M.C. and Frankenburg, F.R. ( 2007) The essential nature of borderline psychopathology. J Pers Disord 21: 518-535.
102. Zanarini, M.C., Frankenburg, F.R., Dubo, E.D., Sickel, A.E., Trikha, A., Levin, A. et al. (1998 a) Axis I comorbidity of borderline personality disorder. Am J Psychiatry 155: 1733-1739.
103. Zanarini, M.C., Frankenburg, F.R., Dubo, E.D., Sickel, A.E., Trikha, A., Levin, A. et al. (1998 b) Axis II comorbidity of borderline personality disorder. Compr Psychiatry 39: 296-302.
104. Zanarini, M.C., Frankenburg, F.R., Hennen, J. and Silk, K.R. ( 2003) The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry 160: 274-283.
105. Zanarini, M.C., Frankenburg, F.R., Khera, G.S. and Bleichmar, J. ( 2001) Treatment histories of borderline inpatients. Compr Psychiatry 42: 144-150.
106. Zanarini, M.C., Frankenburg, F.R. and Parachini, E.A. ( 2004) A preliminary randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 65: 903-907.
107. Zubieta, J.K., Ketter, T.A., Bueller, J.A., Xu, Y., Kilbourn, M.R., Young., E.A. et al. (2003) Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 60: 1145-1153.
108. Zubieta, J.K., Smith, Y.R., Bueller, J.A., Xu, Y., Kilbourn, M.R., Jewett, D.M. et al. (2002) Mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci 22: 5100-5107.